1010 documents

Read All
23:25 , May 6, 2019 |  BC Innovations  |  Translation in Brief

Baby brain organoids link stress response to hypoxic encephalopathy

Brain organoids could help unravel one complication of extremely premature birth: hypoxic encephalopathy. A Stanford group used the technology to zero in on the unfolded protein response as a target for preventing the indication. Encephalopathy...
Read More
19:16 , Apr 26, 2019 |  BioCentury  |  Product Development

For patients’ sake, collaborate already

Cancer immunotherapy companies must stop squandering the most precious stakeholder, patients, and collaborate now on platform trials to test new combination regimens. A straightforward platform trial design that tests different combo partners with PD-1/PD-L1 agents...
Read More
17:29 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

STAG2 identified as target in glioblastoma and Ewing sarcoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma Cell culture studies suggest inhibiting STAG2 could sensitize glioblastoma and Ewing sarcoma to agents that disrupt repair of DNA double-strand (dsDNA) breaks. In two human glioblastoma and one...
Read More
19:34 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting production of PD-L1-loaded exosomes for prostate, colorectal cancers

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer; colorectal cancer Mouse studies suggest inhibiting RAB27A or SMPD3 alone or in combination with anti-PD-L1 antibodies could help treat prostate and colorectal cancers. In a mouse model of prostate...
Read More
22:35 , Apr 8, 2019 |  BC Extra  |  Preclinical News

Tumors release PD-L1 exosomes to evade antitumor immunity

UCSF researchers have found a clue to anti-PD-L1 resistance in exosomes released by tumors, and suggested blocking exosome release as a solution. In a Cell paper published Thursday, the University of California San Francisco team...
Read More
21:48 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Conbriza bazedoxifene for MS and other demyelinating diseases

DISEASE CATEGORY: Autoimmune disease; neurology INDICATION: Multiple sclerosis (MS); neurology Cell culture and mouse studies suggest Conbriza bazedoxifene could help treat MS and other demyelinating diseases. In oligodendrocyte precursor cells (OPCs) derived from a human...
Read More
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
Read More
23:13 , Mar 26, 2019 |  BC Extra  |  Company News

Sana adds hypoimmunogenic stem cell tech from Harvard to its tool kit

Building out its portfolio of cell and gene therapy tools, Sana licensed technology from Harvard University comprising methods to create stem cells that avoid triggering immune rejection when transplanted. The hypoimmunogenic stem cells are derived...
Read More
01:34 , Mar 23, 2019 |  BioCentury  |  Tools & Techniques

A frequentist and a Bayesian walk into a trial

In the stand-off between Bayesians and frequentists, the latter own the show for pivotal trials. But with non-profits leading the drive, Bayesians are poised to enter late-stage development via platform trials in cancer. The next...
Read More
18:38 , Mar 13, 2019 |  BC Extra  |  Company News

FDA qualifies first biomarker test for brain injury

FDA said Tuesday it has qualified a biomarker test tool for use in clinical development of medical devices to treat traumatic brain injury. Developed by the University of California San Francisco’s TBI Endpoints Development Initiative,...
Read More